行情

BCRX

BCRX

BioCryst制药
NASDAQ

实时行情|Nasdaq Last Sale

1.750
+0.165
+10.41%
盘后: 1.790 +0.04 +2.29% 16:44 11/15 EST
开盘
1.700
昨收
1.585
最高
1.820
最低
1.600
成交量
506.13万
成交额
--
52周最高
9.95
52周最低
1.380
市值
1.93亿
市盈率(TTM)
-1.4427
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BCRX 新闻

  • Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially
  • Benzinga.2天前
  • Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially
  • Benzinga.2天前
  • Benzinga's Top Upgrades, Downgrades For November 15, 2019
  • Benzinga.2天前
  • AMAT, JCP among premarket gainers
  • Seeking Alpha - Article.2天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

BCRX 简况

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
展开

Webull提供BioCryst Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。